Background Incomplete excision of cervical precancer is associated with therapeutic failure
and is therefore considered as a quality indicator of clinical practice. Conversely, the risk of …

Detection of persistent cervical carcinogenic human papillomavirus (HPV) DNA is used as a
marker for cervical cancer risk in clinical trials. The authors performed a systematic review …

Background Despite preventive vaccines for oncogenic human papillomaviruses (HPVs),
cervical intraepithelial neoplasia (CIN) is common, and current treatments are ablative and …

The Hippo signaling pathway controls organ size and tumorigenesis through a kinase
cascade that inactivates Yes‐associated protein (YAP). Here, we show that YAP plays a …

Screening programmes involve the systematic offer of testing for populations or groups of
apparently healthy people to identify individuals who may be at future risk of a particular …

Oncogenic HPV types are the major cause of worldwide cervical cancer, but only a small
proportion of infected women will develop high‐grade cervical intraepithelial neoplasia or …

Background: Human papillomavirus (HPV) vaccine may be commercially available in a few
years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 …

A group of 146 experts representing 29 organizations and professional societies met
September 18-19, 2006, in Bethesda, MD, to develop revised evidence-based, consensus …

Background: Little is known about the duration of precancerous cervical lesions in relation to
human papillomavirus (HPV) infection. We estimated rates of progression and regression …

About 25% of high-grade cervical intraepithelial neoplasias (CIN2/3) caused by human
papillomavirus serotype 16 (HPV16) undergo complete spontaneous regression. However …